Medtronic DES matches Boston Scientific option in new study; MedShape scores 510(k) for new surgical tool;

@FierceMedDev: St. Jude Medical's stock spiked again after an analyst upgrade. Story | Follow @FierceMedDev

@MarkHFierce: FierceBiotechResearch's latest--a look at the top 10 U.S. biomedical research institutions. Report | Follow @MarkHFierce

@MichaelGFierce: Sonrgy grabs rights to UCSD-created ultrasound-nanocarrier tech. Item from FierceDrugDelivery | Follow @MichaelGFierce

@EmilyWFierce: ConvaTec is closing its New Jersey facility and cutting jobs. Story | Follow @EmilyWFierce

> A new study concluded that Medtronic's ($MDT) third-generation Resolute Integrity zotarolimus-eluting cardiac stent worked about on par with Boston Scientific's ($BSX) Promus Element everolimus-eluting stent. Story

> Bioresorbable stent developer REVA Medical has hired David Eisler as its new vice president, general counsel. Eisler helped the San Diego company launch its IPO in Australia. Item

> Minnesota startup EmboMedics raised a small series A round to help fuel development of polymer beads that evaporate after releasing drugs into the body. Story

> Expect the med tech industry to experience more digital connectivity, consolidation and transformation in 2014, Medical Marketing & Media reports. Item

> MedShape won 510(k) clearance for a new soft tissue fastener for use during knee joint reconstruction surgery. Item

Biotech News

@FierceBiotech: Another 5 biotechs are queuing up for $278M in IPOs. Is this a bubble after all? More | Follow @FierceBiotech

@JohnCFierce: I'm happy to see the IPO boom, the rise in valuations and all that. But with booms, the bigger they are, the harder they fall. Don't forget. | Follow @JohnCFierce

@DamianFierce: The FDA is giving Sprout's female libido drug another shot in what is becoming a pretty interesting case study. Coverage | Follow @DamianFierce

@EmilyMFierce: The top 10 biomedical research organizations, ranked by NIH funding. Special report | Follow @EmilyMFierce

> The world's two Mercks squabble over who gets to be a household name. Story

> > GlaxoSmithKline R&D chief touts the future of 'electroceuticals.' News

Pharma News

@FiercePharma: Perrigo sees growth, but its sales are trimmed by a hit to contract manufacturing. Story | Follow @FiercePharma

@TracyStaton: Double dose of Merck is too much for German version's CEO. Article | Follow @TracyStaton

@EricPFierce: The best biomedical research facilities in the US may not surprise you. Then again maybe it will. Report | Follow @EricPFierce

@GalenMoore: Particularly for drugmakers strong in diabetes, the Gulf region is a hotbed of activity. Story | Follow @GalenMoore

> Mallinckrodt expands pain portfolio with Cadence acquisition. Piece

> Double dose of Merck is too much for German version's CEO. Story

> What's Big Pharma's latest hot spot? The Middle East. Article

> Pharma-funded group hired by U.K. health service to advise on strategy. News

Biotech Research News

> The top 10 biomedical research institutions. Special Report

> CalTech drug delivery method halts HIV infection in mice. Article

> Nasal vaccine protects mice from West Nile virus. Story

> U.K. pledges to reduce use of animals for biomedical research. News

> Gates Foundation delivers an $11.8M grant to fuel tuberculosis R&D. Story

> New therapeutic target for multiple sclerosis could help repair damaged brain cells. Article

Pharma Manufacturing News

> FDA says products recalled by compounder are contaminated. News

> Teva, which has been tightening its supply chain, turns in a surprising financial report. Story

> Jazz is investing up to $68M to build its first manufacturing facility. Article

> Wockhardt's earnings crash under the weight of FDA bans. News

> The FDA reports far fewer new drug shortages, but the problem continues to grow. Article

> Novartis is expanding a plant in Singapore. Item

Suggested Articles

InterVene secured $15 million to validate its catheter-based treatment for correcting failed one-way valves in the veins of the legs.

LabCorp, Philips and Mount Sinai are coming together to develop an AI-driven pathology center of excellence, aimed initially at cancer diagnosis.

The FDA followed through with plans to end its Alternative Summary Reporting program, making 20 years’ worth of device safety data publicly available.